Immunogenicity of influenza vaccination in children with Inflammatory Bowel Disease
Notice bibliographique
Résumé
Children with inflammatory bowel disease (IBD) are frequently treated with immunosuppressive therapies. Protection against vaccine-preventable diseases is important because of the risk of increased susceptibility and severity of infection with immunosuppressive therapy. However, immunosuppressive therapy may affect response to vaccine. The objective of this study was to evaluate the immunogenic response and the serologic protection to influenza vaccine in children with IBD compared to healthy sibling controls. In this prospective, open-label, controlled study, children with IBD and healthy sibling controls underwent serum collection for pre-immunization hemagglutination inhibition titer. Then the trivalent (A/Brisbane/10/2007 [H3N2], A/Brisbane/59/2007 [H1N1], B/Florida/4/2006 [B]) inactivated influenza vaccine was administered. Three to 5 weeks later, all participants underwent serum collection for post-immunization hemagglutination inhibition titers. An immunogenic response against each influenza strain was defined as a four-fold or greater increase in hemagglutination inhibition titer from pre-immunization to post-immunization. Seroprotection against each influenza strain was defined as a post-immunization hemagglutination inhibition titer of 40 or greater. Children with IBD were classified according to therapy as immunosuppressed (on corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, or tumor necrosis factor-α inhibitor) or nonimmunosuppressed (on aminosalicylates only, antibiotics only, or no therapy). Sixty children with IBD (26 Crohn's disease, 24 ulcerative colitis, 10 indeterminate colitis) and 53 healthy sibling controls completed the study. Overall, the proportion of children with IBD who developed an immunogenic response to H3N2, H1N1, and B strains were 70.0%, 71.7%, and 53.3%, respectively, and serologic protection to H3N2, H1N1, and B strains were 95.0%, 98.3%, and 85.0%, respectively. A lower proportion of children with IBD developed an immunogenic response to B strain compared to sibling controls (53.3% vs 81.1%, p=0.0009). There was no difference between the proportion of children with IBD compared to sibling controls that developed an immunogenic response to H3N2 and H1N1 strains or serologic protection to all 3 strains. A lower proportion of immunosuppressed children with IBD developed serologic protection to B strain compared to nonimmunosuppressed children with IBD (78.6% vs 100%, p=0.02). No serious vaccine-associated adverse events occurred. Overall, children with IBD develop a high prevalence of serologic protection to influenza vaccination. The difference in the higher proportion of children with IBD who developed serologic protection compared to an immunogenic response may be explained by previous influenza vaccination or infection providing serologic protection. Children with IBD, especially those on immunosuppressive therapy, may have less serologic protection against B strains of influenza vaccination. Future studies are required to evaluate the benefit of a booster vaccination in this population.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,002 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».